Responses
Scientific Abstracts
Rheumatoid arthritis - other biologictreatment
SAT0116 Safety and Efficacy of Ara290, a Non-Hematopoietic Erythropoietin Derived Peptide, in a 4 Weeks Phase II Open Label Trial in Patients with Active Rheumatoid Arthritis.
Compose a Response to This Article
Other responses
No responses have been published for this article.